The harness for n‑of‑1 medicine
Why personalized medicine starts with longevity
Personalized medicine is changing the way healthcare is manufactured, delivered, and consumed, and it starts with Longevity.
In this answer11
Is medicine really being built for one person?
In August 2026 a cancer vaccine designed for one patient at a time succeeded in a phase 3 trial (opens in a new tab), and every patient who received it received a different medicine. That is healthcare being manufactured for one person, and longevity is where the same idea is already delivered and consumed every day, before disease: a plan written for one person, carried out over years, and paid for by the patient.
In that phase 3 trial the vaccine was given with a PD‑1 checkpoint inhibitor after surgery for high-risk melanoma, and it cut the risk of recurrence or death by 42% against the checkpoint inhibitor alone, as presented at ESMO in October 2026 (the sponsors’ release (opens in a new tab)).
FDA’s approvals have been moving the same way for years, with more than a third of new therapeutic approvals being personalized in each of the past six years, and its expedited authorization of the first bespoke CRISPR gene-editing therapy developed for an individual patient (Personalized Medicine Coalition, May 2026 (opens in a new tab)).
FDA has also put out two drafts in 2026 for individualized therapies, one on a plausible mechanism framework and one on filing genome-editing variants in a single application (Federal Register, February (opens in a new tab) and October 2026 (opens in a new tab)).
Who pays for medicine built for one person, and who is pushing it?
Patients do, and they are willing to pay an enormous amount of money for it, because at the longevity clinics running the hardest protocols this already looks like trial-grade medicine created for a single person. Every patient at these clinics is a clinical trial of one, followed by their doctor more like a cancer patient, although they don’t have cancer.
At the same time, the demand for biotech is being pushed by frontier labs rather than by life sciences these days, which is a really big shift in the way healthcare is being built in the back end and the way scientific research is being driven.
Is longevity just a lifestyle category?
Much of what gets called longevity is precision medicine happening under people’s noses, as prevention and earlier treatment of specific conditions, while life sciences keeps expanding the indications of the formulations it already has. A diabetes drug has been approved for heart failure (opens in a new tab) and then for chronic kidney disease (opens in a new tab), and a second one has added kidney disease in type 2 diabetes (opens in a new tab) and a serious liver disease, MASH (opens in a new tab). We believe consumer demand is part of what pulls those indications forward, and most people don’t see what is happening under the semantics of longevity, where clinics running n‑of‑1 protocols for long-term patients are bringing it to the point of care.
Why do longevity clinics lead the way?
It’s because the clinic’s unit of care is a protocol that runs for months, and protocols are stacked over years, with certain biomarker changes and possible side effects all closely monitored, as they are in a protocol for a trial (think thousands of biomarkers: genetics, labs, wearables and other clinical observations). Longevity clinics are running “n‑of‑1” trial-grade protocols, and there is no payer, so the clinical record and the commercial record are the same object: the patient is the customer, retention is the business, and it is won across the protocol.
And the plan keeps moving inside those years, with a side effect this week changing a dose within days and a lab result closing one protocol and opening the next, so a doctor has to read every turn of it. The rigor has to be highest at the frontier, where the clinics furthest out already run mTOR inhibition and repurposed drugs on human evidence that is still thin, while senolytics are in early human trials.
Illustrative
Why can’t a clinic run this on its own?
The entire clinical, commercial and regulatory record is falling on the providers because there’s no payer here, so everything a trial protocol asks for lands on the clinic itself: the trial management, the data capture, the safety reporting, the biostatistics and the team of people around it, over years, and no clinic can afford that for a single patient. The field names the gap itself, in a preprint titled “When One Person is the Trial”, which opens on longevity medicine that “still lacks the quality infrastructure that mature health disciplines take for granted” (Preprints.org, September 2026 (opens in a new tab)).
On the regulatory side, a pathway is opening in the United States. In 2023 FDA added nineteen bulk substances, most of them peptides, to its list of those that may present significant safety risks in compounding by pharmacies and physicians, and seventeen have since come off as their nominators withdrew them, five in 2024 and twelve in April 2026 (FDA, April 2026 (opens in a new tab); FDA’s list as it stood in 2023 (opens in a new tab), 2024 (opens in a new tab) and 2026 (opens in a new tab)). FDA still lists an oral ghrelin-receptor agonist for every compounder, a reproductive-axis peptide for pharmacies and physicians, and three growth-hormone-releasing peptides for outsourcing facilities, one of them for its injectable and nasal routes only (FDA, April 2026 (opens in a new tab)).
FDA’s advisory committee has since voted in favor of adding six of the twelve that came off in April 2026 to the list of substances that can be used in compounding, and those six now sit under a draft HHS policy whose notice says that, “to expand and improve patient access,” HHS doesn’t intend to take enforcement action against the pharmacies and physicians compounding them (Federal Register, October 2026 (opens in a new tab); Hall Render, November 2026 (opens in a new tab)). Compounded drugs are not FDA-approved, and this draft approves none of them and, in HHS’s words, “is not binding on HHS or the public”. The notice looks ahead to rulemakings that “may propose adding some or all of these peptides” to that list, “based on the available evidence”.
The human evidence is what this opening now has to build. FDA’s reviewers had recommended against adding any of the six (FDA, July 2026 (opens in a new tab)) and identified no clinical studies or human exposure data for three of them (FDA’s reviews, July 2026: first (opens in a new tab), second (opens in a new tab), third (opens in a new tab)), and a 2026 narrative review of peptides in urology and sexual medicine found safety data across the classes it covered “limited by short follow-up, small samples, and incomplete assessment of cardiovascular, metabolic, and oncologic outcomes” (Sexual Medicine Reviews, 2026 (opens in a new tab)).
The standard comes with the opening. Legal summaries report the draft HHS policy’s conditions for whoever compounds, among them a valid patient-specific prescription, the bulk substance from an FDA-registered facility with a certificate of analysis, and the reporting of serious adverse events and product quality issues (Hall Render, November 2026 (opens in a new tab)), and around the drug the prescribing doctor leads the protocol: the stop rule, the monitoring and the record of what happened. That record is where the evidence begins.
Clinics running these protocols spend significant time hacking together spreadsheets across multiple systems, and get buried in inbound queries from patients at the same time, with doctors spending hours handwriting how each lab has changed because their EHR holds a result as little more than a picture.
Why is this possible now?
Until recently, reading every signal about one patient was too expensive: running a language model across one patient’s record for a year cost several hundred dollars in 2020, and in 2026 it costs between thirty cents and twenty dollars (opens in a new tab). So intelligence is becoming abundant, and the scarce input is now the record of how one person responds to an intervention over years.
Measuring that response is now the live scientific question, because no clinically important difference has been defined for an epigenetic clock (Nature Medicine, August 2026 (opens in a new tab)), and within one person a clock’s score moves from one draw to the next within a day, in no set direction, even though the same tube run twice agrees (Aging Cell, August 2026 (opens in a new tab)). So what counts as a real change in one person is a change larger than that marker’s own variation across repeat draws, a clock stays context, and function, measured as VO2 max and grip strength, drives the doctor’s decisions with the conventional markers.
Where does iksa, the harness for n‑of‑1 medicine, come in?
iksa runs the whole loop on one record. We built it as an AI lab inside longevity, and we’ve trained our clinical-commercial harness to drive a clinic in the most efficient way possible. It will only compound as the models get better, because it is a unified system of record: each leap in AI lands inside the clinic’s own workflows and protocols, under safety rules set with its doctors for what reaches a patient. Clinics take it on for capacity and retention they can read on their own dashboards, and we run iksa itself on the architecture we sell to them, shipping a release every week.
Questions about the thesis? Talk to the team behind it.
Talk to usWhat does running the protocol this way open?
That makes iksa a harness for the most precise clinical planning today, and for research, studies and the scaling of precision medicine as the record deepens. If you run the protocol properly, the evidence falls out of care: longevity clinics generate, every day, the record of how one person responded to an intervention, for interventions no sponsor runs at scale. Our vision is to work on that evidence with clinics and life-sciences partners one study at a time, on de-identified data, with patient consent, under terms written into each clinic’s agreement.
Why does biotech need what these clinics see?
Because in a cash-pay environment all of that care is invisible to the claims and EHR data life sciences buys, and FDA’s own guidance says so of the medicines: “EHRs and medical claims data may not systematically capture the use of nonprescription drugs or drugs that are not reimbursed under health plans” (FDA, July 2024 (opens in a new tab)). The record of how one person responded lives at the point of care.
So every protocol produces the evidence regulators require and life sciences acquires, and that is what opens partnerships with biotechs for decentralized trials, starting from patients already in care with a doctor they know.
The developers on the other side of that record have 4,487 gene, cell and RNA therapies in development (ASGCT and Citeline, July 2026 (opens in a new tab)).
Where does biotech meet the patient first?
Inside the clinic, where research and investment run, because some of these provider groups are building micro-ecosystems that centralize biotech and investment and clinical research at the point of care rather than in larger life sciences studies.
How big does this get?
The long-term vision for iksa is to change the way healthcare is manufactured, delivered, and consumed. We believe in a future of medicine where every personalized protocol is chosen from evidence of what worked for patients like this one.
The vision is autonomous personalized medicine in dispersed micro-ecosystems globally operating at trial-grade. Long term, iksa becomes the Flatiron of personalized medicine, sitting between the clinics running the hardest protocols and the biotechs formulating what they run.
We believe this grows because cash-pay medicine is the future of healthcare and it is going to take reimbursement years to catch up with the way consumers are actually interacting with it. As care gets more personalized and more concierge, with protocols stacked over years, people will pay the premium for results they can follow over time, and we believe that premium goes to the clinics that can show their evidence.
This medicine is already taking many forms, and we’re seeing a wide spectrum of practices move this way, across longevity, anti-aging, concierge medicine, women’s health, men’s health, hormone therapy, GLP‑1 and metabolic health, peptide therapy, regenerative medicine, functional medicine and integrative oncology, and everybody in it wants to service the hardest protocols, so every other clinic benchmarks against the leaders and runs a subset of what they run.
Patients already pay for their own health at an enormous scale, and in five years the practices they pay to join nearly doubled while corporate owners moved in
Running these protocols in your clinic?
Bring a protocol you run. We’ll walk one patient through it.